10 ≥ 1% от пациентите при всяка от лекуваните група по време на едногодишното проучване или при ≥ 1% от пациентите, лекувани с алендронат 10 mg дневно и с по- висока честота от тази в групата на плацебо по време на тригодишните проучвания.
Adverse reactions reported by the investigators as possibly, probably or definitely related to the active substance are presented below if they occurred in ≥ 1% of any in the treatment groups in the one-year study or in ≥ 1% of the patients who were treated with alendronate 10 mg per day and with an incidence higher than in patients who were treated with placebo in three-year studies.